Shanghai Henlius Biotech, Inc. Class H (2696) Income Statement

Last quarter (Q4 2024), Shanghai Henlius Biotech, Inc. Class H's total revenue was ¥1.49B, an increase of 1.50% from the same quarter last year. In Q4, Shanghai Henlius Biotech, Inc. Class H's net income was ¥217.08M. See Shanghai Henlius Biotech, Inc. Class H’s key income statements, including revenue, expenses, profit, and income.